850374-95-7

Basic information

• Product Name: 1-TERT-BUTYL 6-METHYL 3-FORMYL-1H-INDOLE-1,6-DICARBOXYLATE
• Synonyms: 1-TERT-BUTYL 6-METHYL 3-FORMYL-1H-INDOLE-1,6-DICARBOXYLATE;3-FORMYL-6-(METHOXYCARBONYL)-1H-INDOLE, N-BOC PROTECTED
• CAS NO: 850374-95-7
• Molecular Formula: C₁₆H₁₇NO₅
• Molecular Weight: 303.31
• Mol File: 850374-95-7.mol

Chemical Properties

• Melting Point: 214 °C
• Boiling Point: 443.3°C at 760 mmHg
• Flash Point: 221.9°C
• Appearance: /
• Density: 1.2g/cm³
• Vapor Pressure: 4.7E-08mmHg at 25°C
• Refractive Index: 1.553
• CAS DataBase Reference: 1-TERT-BUTYL 6-METHYL 3-FORMYL-1H-INDOLE-1,6-DICARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-TERT-BUTYL 6-METHYL 3-FORMYL-1H-INDOLE-1,6-DICARBOXYLATE(850374-95-7)
• EPA Substance Registry System: 1-TERT-BUTYL 6-METHYL 3-FORMYL-1H-INDOLE-1,6-DICARBOXYLATE(850374-95-7)

Safety Data

• Hazardous Substances Data: 850374-95-7(Hazardous Substances Data)

Usage

Uses

Given the lack of specific applications provided in the materials, potential uses for 1-TERT-BUTYL 6-METHYL 3-FORMYL-1H-INDOLE-1,6-DICARBOXYLATE can be hypothesized based on its chemical class and structural components:
Used in Pharmaceutical Industry:
1-TERT-BUTYL 6-METHYL 3-FORMYL-1H-INDOLE-1,6-DICARBOXYLATE could be utilized as an active pharmaceutical ingredient (API) for the development of new drugs, leveraging its indole core and functional groups to target specific biological pathways or receptors. 1-TERT-BUTYL 6-METHYL 3-FORMYL-1H-INDOLE-1,6-DICARBOXYLATE's potential use in this industry would be driven by its ability to interact with biological systems, possibly leading to therapeutic effects.
Used in Agrochemical Industry:
In the agrochemical sector, 1-TERT-BUTYL 6-METHYL 3-FORMYL-1H-INDOLE-1,6-DICARBOXYLATE might serve as a precursor to the synthesis of bioactive molecules with pesticidal or herbicidal properties. Its use would be justified by its capacity to influence plant or pest metabolism, offering a new approach to crop protection.
Used in Materials Science:
For materials science applications, 1-TERT-BUTYL 6-METHYL 3-FORMYL-1H-INDOLE-1,6-DICARBOXYLATE could be explored for its potential to form novel polymers or composites with unique properties. Its use in this field would be based on the compound's ability to contribute to material properties such as conductivity, stability, or responsiveness to environmental stimuli.

InChI:InChI=1/C16H17NO5/c1-16(2,3)22-15(20)17-8-11(9-18)12-6-5-10(7-13(12)17)14(19)21-4/h5-9H,1-4H3

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 133831-28-4 methyl 3-formyl-6-indolecarboxylate 

Downstream Products

• 1428969-28-1 3-(2-((3-methoxyphenyl)amino)-2-phenylacetyl)-1H-indole-6-carboxylic acid 
• 1428968-68-6 methyl 3-(2-((3-methoxyphenyl)amino)-2-phenylacetyl)-1H-indole-6-carboxylate 
• 1428968-62-0 methyl 3-(2-((2-methoxypyridin-4-yl)amino)-2-phenylacetyl)-1H-indole-6-carboxylate 

Relevant articles and documents

Structure-guided design, synthesis, and biological evaluation of (2-(1 H-Indol-3-yl)-1 H-imidazol-4-yl)(3,4,5-trimethoxyphenyl) methanone (ABI-231) analogues targeting the colchicine binding site in Tubulin

ABI-231 is a potent, orally bioavailable tubulin inhibitor that interacts with the colchicine binding site and is currently undergoing clinical trials for prostate cancer. Guided by the crystal structure of ABI-231 in complex with tubulin, we performed structure-activity relationship studies around the 3-indole moiety that led to the discovery of several potent ABI-231 analogues, most notably 10ab and 10bb. The crystal structures of 10ab and 10bb in complex with tubulin confirmed their improved molecular interactions to the colchicine site. In vitro, biological studies showed that new ABI-231 analogues disrupt tubulin polymerization, promote microtubule fragmentation, and inhibit cancer cell migration. In vivo, analogue 10bb not only significantly inhibits primary tumor growth and decreases tumor metastasis in melanoma xenograft models but also shows a significant ability to overcome paclitaxel resistance in a taxane-resistant PC-3/TxR model. In addition, pharmacological screening suggested that 10bb has a low risk of potential off-target function.

VIRAL REPLICATION INHIBITORS

The present invention relates to a series of novel compounds, methods to prevent or treat viral infections in animals by using the novel compounds and to said novel compounds for use as a medicine, more preferably for use as a medicine to treat or prevent viral infections, particularly infections with RNA viruses, more particularly infections with viruses belonging to the family of the Flaviviridae, and yet more particularly infections with the Dengue virus. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of viral infections. The invention also relates to processes for preparation of the compounds.